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Multiple reaction monitoringAlzheimer’s disease has been shown to have a global reduction in gene expression, called an
epigenetic blockade, which may be regulated by histone post-translational modiﬁcations. Histone
H3 has been shown to be highly regulated by phosphorylation. We, therefore, chose H3 for investiga-
tion of phosphorylation of the core sites serine-57 (S57) and threonine-58 (T58). Hemispheres of
brains from a mouse model of rapid amyloid deposition (5XFAD) were used for measurement of
S57 and T58 phosphorylation. Multiple reaction monitoring (MRM) was used to measure the level
of phosphorylation, which was normalized to a non-modiﬁed ‘‘housekeeping’’ peptide of H3. S57
phosphorylation was decreased by 40%, T58 phosphorylation was decreased by 45%, and doubly
phosphorylated S57pT58p was decreased by 30% in 5XFAD brain in comparison to C57BL/6J
age- and sex-matched wild type controls. Amyloid-b (Ab) and amyloid precursor protein were also
measured to conﬁrm that 5XFAD mice produced high levels of Ab. Decreased phosphorylation of
these sites in close proximity to DNA may lead to stabilization of DNA–histone interactions and a
condensed chromatin state, consistent with the epigenetic blockade associatedwith AD. Our ﬁndings
of H3 sites S57 and T58 exhibiting lower levels of phosphorylation in 5XFADmodel compared to wild
type control implicate these sites in the epigenetic blockade in neurodegeneration pathology.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction One common PTM on histones is phosphorylation of serine (Sp)Alzheimer’s disease (AD) is the most common neurodegenera-
tive disorder and is the sixth leading cause of death in the U.S.
[1]. The cause of AD is still not well understood and there is no
disease-modifying treatment to delay onset or slow progression
[2,3]. Epigenetics of AD is a growing ﬁeld that has gained interest
due to the repression of gene transcription, an epigenetic blockade,
that is consistently observed in AD [4,5]. Among these changes
associated with gene repression are post-translational modiﬁca-
tions (PTMs) of histones, which can alter histone–DNA and
inter-nucleosome interaction and, in turn, chromatin structure
[6]. PTMs are largely found on the N-terminal domains, commonly
referred to as tail regions, that extend from the histone core com-
plex. Little information exists on PTMs in the core region of
histones.and threonine (Tp) residues, which has been linked to activation
and repression of genes based on site of modiﬁcation and condition
of cells [7–9]. Serine phosphoacceptor sites are found on the tail
regions of all core histones [10]. Phosphorylation of S10 on histone
H3 (H3S10p) has been extensively studied for its roles in conden-
sation of chromatin during mitosis [8,9] and to a lesser extent in
neurodegenerative disorders, such as AD [11]. While many types
of PTMs on histone tails have been associated with disease, little
information exists on PTMs in the core region of histones. It is sug-
gested that phosphorylation of H3 may be particularly meaningful
compared to other core histones [7,12,13]. Speciﬁcally in the core
region of H3, there are several potential threonine and serine phos-
phorylation sites, but exploration of their signiﬁcance has been
minimal. H3T45p is directly correlated with apoptosis [14],
H3T80p is increased in mitosis [15], and H3T118p destabilizes
the nucleosome [16]. However, little is known about H3S57 and
H3T58 phosphorylation roles in normal biological functions and
there is no information to date describing changes in these phos-
phorylation sites in AD brain. H3S57p has been detected in mam-
malian cells and may have implications in response to DNA
damage based on studies in yeast [17]. H3T58p has not been
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potential phosphorylation sites on the surface of the nucleosome
which could be easily accessible to kinases and phosphatases and
found that S57 and T58 are located on the surface. Speciﬁcally,
these adjacent residues occur in an accessible turn of a
helix-turn-helix motif of H3 in close proximity to DNA, which sug-
gests these sites may engage in regulatory phosphorylation and
supports investigation into these sites in brain and AD pathology.
AD is characterized by deposition of amyloid-b (Ab) plaques and
neuroﬁbrillary tangles of tau protein as well as dementia. The Ab
peptide is contained in the amyloid precursor protein (APP), a large
integral membrane protein concentrated in neurons. In AD, APP
undergoes processing by membrane-anchored proteases, called
secretases, producing the amyloidogenic isoform Ab42. The
c-secretase complex, consisting of protein nicastrin, APH1, PEN2,
and presenilin 1 (PS1) or PS2, executes the C-terminal cleavage
of Ab, releasing the intracellular domain (ICD) of APP into the cyto-
plasm. In addition to releasing the ICD of APP, c-secretase can also
cleave Notch and other proteins. Released ICDs may act as signal-
ing molecules, for example the Notch ICD can activate nuclear sig-
naling pathways [18]. Released Ab may form neurotoxic oligomers
or aggregate into senile plaques in the extracellular environment
[19]. To mimic the amyloid pathology found in humans with AD,
transgenic mice with genetic mutations that cause rapid amyloid
deposition have been created as models of AD pathology [20].
One of these models, called 5XFAD mice, overexpress two human
proteins with ﬁve mutations of familial AD: PS1 with M146L and
L286V and APP695 with Swedish (K670N, M671L), Florida
(I176V), and London (V717I) mutations. In addition to vast over-
production of Ab42, these 5XFAD mice also display cognitive
impairment consistent with dementia [20]. We used the 5XFAD
mouse model of rapid amyloid deposition as our subject for inves-
tigation of H3 phosphorylation at S57 and T58 sites.
Our study shows that phosphorylation of both S57 and T58 on
histone H3 is lower in 5XFAD models of amyloid deposition in
comparison to wild type controls. Since changes in PTMs of his-
tones are established to inﬂuence genetic expression, our measure-
ments of speciﬁc histone H3 residues S57 and T58 may provide
insight into the epigenetic blockade phenomenon in the pathology
of neurodegeneration.
2. Material and methods
The DC Protein Assay kit was purchased from Bio-Rad
Laboratories (Hercules, CA). RapiGest SF surfactant was from
Waters (Milford, MA), Trypsin (T0303, Type IX-S from porcine pan-
creas) and all other chemicals were purchased from Sigma–Aldrich
(St. Louis, MO).
2.1. Mice
All animal-handling and experimentation performed was
approved by the Institutional Animal Care and Use Committee at
Case Western Reserve University. 5XFAD [20] mice were main-
tained by crossing 5XFAD hemizygous males on B6SJL background
(The Jackson Laboratory) with B6SJL females (The Jackson
Laboratory, stock 100012). Only F1 males homozygous with
respect to the transgene were used. Wild type C57BL/6J mice
(The Jackson Laboratory, stock 000664), a common laboratory
strain that do not develop amyloid plaques and the progenitor
strain used to make transgenic 5XFAD, were used as control.
Mice were housed in the Animal Resource Center at Case
Western Reserve University and maintained in a standard 12 h
light/12 h dark cycle environment. Water and food were provided
ab libitum. 5XFAD male mice (n = 3) and C57BL/6J age- andsex-matched wild type controls (n = 3) were sacriﬁced at 3 months
of age to assess the differences.
2.2. Whole mouse brain processing
Hemispheres of brains were harvested and ﬂash-frozen in liquid
nitrogen for storage at 80 C. Left hemispheres of the brain were
ﬁnely minced with a scalpel blade and homogenized in 25 mmol/L
NH4HCO3 by sonication at 30 W using ﬁve, 10 s continuous cycles
(Sonicator 3000, Misonix Inc., Farmingdale, NY). Total protein con-
centration of the homogenate was measured using a DC protein
assay kit in the presence of 1% (mass fraction) sodium dodecyl sul-
fate (SDS) with bovine serum albumin as the standard.
Homogenates were aliquoted and stored at 80 C. Samples of
3 mg total protein were supplemented with 12 pmol APP
QconCAT standard [21] and treated with 20 mmol/L dithiothreitol
(DTT) and 1% (mass fraction) SDS. After 1 h incubation at room
temperature to reduce cysteines, 55 mmol/L iodoacetamide was
added and incubated an additional 1 h to alkylate cysteines.
Chloroform/methanol precipitation was used to isolate proteins.
Protein pellets were then sonicated in 1 mL 25 mmol/L
NH4HCO3/0.1% (mass fraction) RapiGest SF surfactant and treated
with trypsin at 25:1 protein:trypsin mass ratio overnight at
37 C. After trypsinolysis, 0.5% (volume fraction) triﬂuoroacetic
acid (TFA) was added and incubated at 37 C for 1 h to cleave
acid-labile RapiGest SF surfactant, which was subsequently
removed by centrifugation at 179,000g for 30 min at 4 C.
Supernatants were dried in an Eppendorf AG Vacufuge
(Hamburg, Germany), yielding ﬁnal peptides for analysis.
2.3. LC–MS/MS analysis
Dried peptides were reconstituted in 3% acetonitrile, 97% water,
and 0.1% formic acid (volume fraction). Separation was performed
on an Agilent Zorbax Eclipse Plus C18 RRHD column
(2.1 mm  50 mm, 1.8 lm particle) and multiple reaction monitor-
ing (MRM) analysis was performed on an Agilent 6490 iFunnel
Triple Quadrupole LC/MS system (Santa Clara, CA). Peptides were
eluted at a ﬂow rate of 200 lL/min using the following gradient
of solvent B in solvent A: 3% B for 3 min, 3–30% B in 32 min, 30–
50% B in 5 min, and 50–3% B in 3 min. Solvent A was water contain-
ing 0.1% (volume fraction) formic acid and solvent B was acetoni-
trile containing 0.1% formic acid. The acquisition method used
the following parameters in positive mode: fragmentor 380 V, col-
lision energy 20 V, dwell time 100 ms, cell accelerator 4 V, electron
multiplier 500 V, and capillary voltage 3500 V. MRM transitions for
2+ charge precursor ions and 1+ charge product ions were pre-
dicted using PinPoint software (Thermo Fisher Scientiﬁc,
Waltham, MA).
2.4. Data analysis for APP and Ab
Quantiﬁcation of total APP and Ab in mouse brain samples,
using MRM with QconCAT as an internal standard [21], was per-
formed to conﬁrm that the 5XFAD model of amyloid pathogenesis
produced signiﬁcant Ab in comparison to the control. A QconCAT is
a recombinant protein containing concatenated peptides used for
multiplexed quantiﬁcation of proteins [22]. The QconCAT standard
used contained peptides for both APP and Ab [21] and was supple-
mented into homogenates prior to processing to increase precision
and accuracy of measurements. Based on sequence speciﬁcity and
measured intensity, a single peptide, LVFFAEDVGSNK, was selected
from Ab and two peptides, VESLEQEAANER and AVIQHFQEK, were
selected to measure total APP. APP is large transmembrane protein
that undergoes processing to release the fragment Ab. Therefore,
Fig. 1. Peptide identiﬁcation by MRM and selection of transitions for quantiﬁcation. (A, D and F) Numerous transitions were monitored to determine retention time and
conﬁrm identity of each peptide. (B, E and H) Spectra of ions used to conﬁrm identity and site of phosphorylation. (C, F and I) A single transition was selected from each
peptide for quantiﬁcation. *Transition 425.72? 409.21 had high signal intensity and was removed from chromatogram (G) and reduced in spectrum (H) to better illustrate
other monitored transitions.
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Measurements for Ab are inclusive of the Ab fragment and unpro-
cessed APP, which still contains Ab. These peptides were included
in a stable isotope labeled QconCAT standard, as previously
described [21], which was supplemented into samples.
Quantiﬁcation of APP and Ab was performed by calculating the
ratio of peak areas for unlabeled biological peptides to labeled
standard peptides using MassHunter software (Agilent)multiplying by the ratio of known picomoles of standard to mil-
ligrams of total protein. Protein concentrations are presented as
pmol/mg and represent the mean ± standard deviation (SD) of pep-
tide transitions associated with each protein. Statistical signiﬁ-
cance of mean differences was calculated using Student’s
two-tailed t-test and was considered signiﬁcant if p 6 0.05.
Transitions used for quantiﬁcation of APP and Ab are presented
in Supplementary Table S1.
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All selected MRM transitions were used to conﬁrm the identity
of each peptide for each LC–MS analysis and a representative tran-
sition for each peptide was chosen for quantiﬁcation. Quantitative
transitions were stable in replicate injections and produced signal
reasonable for comparison to those of other peptides. Additionally,
the ratio of quantitative transitions to respective transitions for
each precursor was consistent across biological samples, indicating
quantitative transitions were not biased. A list of all transitions for
identiﬁcation and quantiﬁcation are available in Supplementary
Table S2. Peak areas of quantitative transitions were calculated
using MassHunter software from Agilent. Peak areas of phosphory-
lated peptides were normalized to peak area of calibrant peptide,
EIAQDFK, found in the core of H3. EIAQDFK was initially screened
in both control and 5XFAD mice for any PTMs and none were
detected, allowing for its use as a calibrant peptide. Triplicate bio-
logical replicates, each with triplicate analytical replicates, pro-
duced n = 9 normalized ratios, which were averaged together and
presented as mean ± standard deviation. Statistical signiﬁcance of
mean differences was calculated using Student’s two-tailed t-test.
An example of calculations from raw integrated peak areas to nor-
malized and averaged values is presented in Supplementary
Table S3.
3. Results and discussion
3.1. Preparation of brain samples for measurement
To minimize unwanted loss of phosphorylation, SDS was added
to tissue homogenates at the very ﬁrst step of sample processing
to arrest enzymatic activity. Early addition of SDS also efﬁciently
denatures proteins [23,24] and evenly exposes Cys residues in all
samples to subsequent reduction and alkylation. The main H3
variants, H3.1, H3.2, and H3.3, all contain a cysteine at position
110 that is known to undergo disulﬁde bonding to form an H3
dimer. H3.1, in addition, contains a cysteine at position 96 that
participates in disulﬁde bonding [25,26]. A challenge to processing
brain tissue for MS analysis is its high lipid content, which can
degrade chromatography performance and contribute to ion
suppression. The whole brain is approximately 80% lipid by
dry mass [27] and, therefore, necessitates removal of lipids.
Chloroform/methanol precipitation of the protein efﬁciently
removed lipids, SDS, salts, and by-products alkylation to yield a pureFig. 2. Quantiﬁcation of APP and Ab in 5XFAD and control. (A) Amyloid precursor protein,
for Ab (red). Ab is released as a fragment peptide during processing of APP by b- and c-sec
APP and free Ab. Total APP peptides AVIQHFQEK and VESLEQEAANER and Ab peptide LVF
mice (n = 3) and (C) 5XFAD mice (n = 3). Measurements represent mean ± standard dev
transitions for VESLEQEAANER, and four transitions for LVFFAEDVGSNK for absolute quprotein pellet. These two major steps, (i) early addition of SDS fol-
lowed by reduction/alkylation of Cys residues and (ii) chloro-
form/methanol precipitation to increase protein purity, ensure
sample quality compatible with LC–MS/MS analyses, while mini-
mizing processing to maintain endogenous phosphorylation.
Additionally, all samples were processed in parallel to ensure that
no artiﬁcial loss of phosphorylation would create a bias between
samples groups and that observed differences between groupswere
purely of biological origin.
3.2. Selection of transitions for MRM
The main histone H3 variants, H3.1, H3.2, and H3.3, have very
close homology, which is evidenced by their sequence alignment
(Supplementary Fig. S1). Initially, all selected transitions for pep-
tides containing only S57p, only T58p, or both S57p and T58p were
used to identify and conﬁrm retention times of peptides in each MS
chromatogram (Fig.1). With the speciﬁcity of MRM and consensus
of six or more transitions for each peptide, peptide identiﬁcation
was performed with certainty. The most abundant, unique transi-
tion for each peptide was then used for quantiﬁcation using inte-
grated peak area. By selecting the most abundant transition for
quantiﬁcation, peak area could be more reproducibly and accu-
rately measured. Transitions used for identiﬁcation and quantiﬁca-
tion can be found in Supplementary Table S2. Our measurements
using this method of relative quantiﬁcation enable comparison of
the level of change in S57 and T58 phosphorylation in the AD
model 5XFAD to control.
3.3. APP and Ab in 5XFAD brain
Mice with rapid amyloid deposition (5XFAD) [20] were com-
pared to age- and sex-matched wild type C57BL/6J mice. 5XFAD
provide an appropriate model for AD-related amyloid pathogenesis
for the exploration of amyloid-associated changes [28]. Ab was
460 ± 70 pmol/mg total protein in 5XFAD mouse brain, a 177-fold
greater concentration than the 2.6 ± 0.2 pmol/mg in control
(Fig. 2). APP was 54 ± 3 pmol/mg in 5XFAD, 13-fold greater than
the 4.1 ± 0.5 pmol/mg in control (Fig. 2). The signiﬁcant increase
in APP and Ab indicates the presence of amyloid pathology in the
5XFAD mouse brain. Since the amino acid sequence for Ab is pre-
sent in both free Ab and unprocessed APP (Fig. 2A), it is of interest
to compare the level of Ab to APP to verify that Ab concentration
increases were not largely attributed to unprocessed APP. InAPP, (gray) is a large transmembrane protein that contains the amino acid sequence
retases. Therefore, measurements for Ab include the peptide present in unprocessed
FAEDVGSNK were measured in whole hemisphere homogenates from (B) wild type
iation of biological replicates (n = 3) using three transitions for AVIQHFQEK, four
antiﬁcation using QconCAT as internal standard. ***p < 0.001.
Fig. 3. Effect of 5XFAD model on S57 and T58 phosphorylation. Phosphorylation
was measured in whole hemisphere homogenates from mixed wild type mice
(n = 3) and 5XFAD mice (n = 3). Measurements represent mean ± standard deviation
of biological and analytical replicates (n = 9) normalized to respective phosphory-
lation site in mixed wild type control. **p < 0.01; ***p < 0.001.
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concentration to 2.6 ± 0.2 pmol/mg of Ab. However, in 5XFAD, the
460 ± 70 pmol/mg of Ab is nearly 9-fold greater than the
54 ± 3 pmol/mg of APP, indicating a large increase in Ab not attrib-
uted to unprocessed APP. Additionally, our inclusion of SDS and
RapiGest denaturants facilitated the unfolding and solubilizationFig. 4. Proximity of H3 S57 and T58 to DNA. (A) S57 is less than 1.1 nm from DNA and (B)
sites in red. Distance measurements were performed in PyMOL Molecular Graphics System
[29]. (C) Surface view of phosphorylated S57 and T58 on histone core (green) in close pr
(gray). All modeling was performed in PyMOL and insertion of phosphate groups was pof Ab for proteolysis, therefore our measurements represent the
total amount of solubilized Ab. Our measurements conﬁrm that
5XFAD mice produce signiﬁcantly more Ab than control mice in
the brain (Fig. 2). Our ﬁndings validated the use of 5XFAD as a
model of rapid amyloid pathogenesis for subsequent quantiﬁcation
of phosphorylation of S57 and T58 residues.
3.4. S57 and T58 phosphorylation of 5XFAD brain
A representative transition for each peptide was chosen for
quantiﬁcation of phosphorylation. Quantitative transitions were
stable in replicate injections and produced good signals for com-
parison. Moreover, the ratio of quantitative transitions to other
transitions from the same precursor was consistent across biolog-
ical samples, indicating quantitative transitions were not biased.
Peak areas of transitions from phosphorylated peptides were nor-
malized to peak area of transition from calibrant peptide,
EIAQDFK, found in the core of H3 (Supplementary Table S3). Data
was obtained from three mice per sample group and each mouse
was analyzed in triplicate (n = 9 total measurements) to properly
assess statistically signiﬁcant differences between sample groups.
As compared to C57BL/6J mice, 5XFAD showed a 40% lower
level of S57p, 45% lower level of T58p, and a 30% lower level of
simultaneously phosphorylated S57p and T58p (Fig. 3). The
decrease in phosphorylation of S57 and T58 might have an impact
on nucleosome stability. S57 is less than 1.1 nm from DNA (Fig. 4A)
and T58 is less than 0.9 nm from DNA (Fig. 4B) in the crystal struc-
ture of the human nucleosome, PDB ID: 2CV5 [29]. These distancesT58 is less than 0.9 nm from DNA. DNA is shown in gray, H3 in blue, and S57 and T58
Version 1.7.2 using the crystal structure of the human nucleosome (PDB ID: 2CV5)
oximity to the interface of the positively charged phosphate backbone (red) of DNA
erformed using a PyMOL plugin called PyTMs [30].
Fig. 5. Location of H3 residues S57 and T58 within nucleosome. (A) Core histones (green), with ﬂexible histone tails truncated in structure, is shown wrapped in DNA (gray).
The S57T58 regions (spheres with oxygen in red and nitrogen in blue) are in the turn of a helix-turn-helix motif that brings the residues in close proximity to DNA and are
easily accessible to kinases and phosphatases. (B) Phosphorylated S57 and T58 create a repulsive charge–charge interaction with negatively charged DNA, weakening the
afﬁnity of the nucleosome. (C) Dephosphorylation of S57 and T58 greatly reduces negative charge on the histone interface, strengthening the afﬁnity of the DNA–histone
interaction. Modeling was performed using PyMOLMolecular Graphics System Version 1.7.2 and the crystal structure of the human nucleosome (PDB: 2CV5) [29]. Insertion of
phosphate groups was performed using the PyTMs plugin [30].
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1.7.2, Schrödinger, LLC). Phosphorylation of S57 and T58 causes a
signiﬁcant increase in negative charge in close proximity to the
negatively charged phosphate backbone of DNA (Fig. 4C).
Furthermore, both residues are on the histone surface and are posi-
tioned in a turn of a helix-turn-helix motif of the H3 polypeptide
chain, highlighting the ease of access by modifying enzymes
(Fig. 5A). Introduction of phosphoryl groups, about 0.25 nm in size,
in close proximity to the negatively charged backbone of DNA can
weaken DNA–histone interactions [16] (Fig. 5B). Conversely,
dephosphorylation, as observed in 5XFAD (Fig. 5C), can strengthen
nucleosome stability and lead to condensed chromatin with
reduced gene expression [16], consistent with AD pathology
[4,5]. Our measurements reveal dephosphorylation of S57 and
T58 in 5XFAD, which may illustrate speciﬁc epigenetic changes
that occur in AD.
In summary, we demonstrate that MRM assay can provide rel-
ative quantiﬁcation of phosphorylation of histone H3 residuesS57 and T58 in lipid-rich, whole mouse brain homogenates. We
show that levels of S57p, T58p, and doubly phosphorylated S57
and T58 decrease in 5XFAD mice. This suggests these histone
PTMs play an epigenetic role in AD pathology and may stabilize
nucleosomes, causing decreased gene transcription. Our measure-
ments contribute to the overall understanding of AD pathology and
may provide clinical targets for pharmaceutical intervention.
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